Quotient Limited to Host Key Opinion Leader Webinar on its MosaiQ™ Solution
May 12 2022 - 8:30AM
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics
company, today announced that it will host a key opinion leader
(KOL) webinar on the current landscape and unmet needs within blood
grouping and donor disease screening on Monday, May 23, 2022 at
11:00am ET.
The virtual webinar will feature a presentation
with slides from KOL Christophe Martinaud, MD, PhD followed by
comments from Manuel O. Méndez, Chief Executive Officer of Quotient
on its MosaiQ solution, designed to provide multimodal, multiplexed
testing on a fully automated platform, delivering clinical and
economic value to customers while transforming patient care.
A live question and answer session will follow.
To register for the event, please click here.
Christophe Martinaud, MD,
PhD is a medical doctor, specialist in laboratory
medicine and a scientist focused on hemorrhagic shock. He is
currently the medical director and the head of the Department of
Medical Laboratories in charge of quality control, blood donation
screening and immuno-hematological analysis of a French Blood Bank,
which is is also a training and research center embracing blood
products and cell therapy.
Prof. Christophe Martinaud works on
French Lyophilized plasma and was the first to report data about
its use in clinical routine. He focused his research in this field
on hemostatic properties, clinical trials in civilian and military
settings and hemovigilance reporting. Prof.
Christophe Martinaud is professor of transfusion
medicine, Vice-President of the French Society of Blood Transfusion
and member of several experts’ board at the French Regulation
Agency.
About Quotient Limited
Building on over 30 years of experience in
transfusion diagnostics, Quotient is a commercial-stage diagnostics
company committed to delivering solutions that it believes reshape
the way diagnostics are practiced. MosaiQ, Quotient’s proprietary
multiplex microarray technology, offers the world’s first fully
automated, consolidated testing platform, allowing for multiple
tests across different modalities. MosaiQ is designed to be a
game-changing solution, which Quotient believes will increase
efficiencies, improve clinical practice, deliver significant
workflow improvements, and create operational cost savings to
laboratories around the world. Quotient's operations are based in
Switzerland, Scotland and the US.
Forward Looking Statements
This news release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements may include statements regarding our
expectations of continued growth, the development, regulatory
approval, commercialization and impact of MosaiQ and other new
products (including the potential for using the Company’s MosaiQ
technology to infectious disease diagnostics), current estimates of
fourth quarter and full year fiscal 2022 operating results and
expectations regarding our future funding sources. Such statements
are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include delays or denials of regulatory
approvals or clearances for products or applications; market
acceptance of our products; the impact of competition; the impact
of facility expansions and expanded product development, clinical,
sales and marketing activities on operating expenses; delays or
other unforeseen problems with respect to manufacturing, product
development or field trial studies; adverse results in connection
with any ongoing or future legal proceedings; continued or
worsening adverse conditions in the general domestic and global
economic markets, including as a result of the global COVID-19
pandemic; as well as the other risks set forth in the Company's
filings with the Securities and Exchange Commission. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Quotient
disclaims any obligation to update these forward-looking
statements.
The Quotient logo, Quotient MosaiQ and MosaiQ
are registered trademarks or trademarks of Quotient Limited and its
subsidiaries in various jurisdictions.
CONTACT: Investor Relations,
ir@quotientbd.com; +41 22 545 52 26
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Apr 2023 to Apr 2024